Epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 1b/2 EPCORE CLL-1 trial expansion cohort

被引：0
|
作者：
Kater, Arnon
Eradat, Herbert
Niemann, Carsten
Offner, Fritz
Poulsen, Christian Bjorn
Hoyer, Thor
Bellido, Mar
Shadman, Mazyar
Oki, Toshihiko
Kuznetsova, Alexandra
Rios, Marcia
Valentin, Rebecca
Bentzen, Hans Herluf
机构：
来源：
LEUKEMIA & LYMPHOMA | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1546171
引用
收藏
页码：S2 / S3
页数：2
相关论文
共 50 条
  • [41] A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 19 - 20
  • [42] A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL)
    Nabhan, C
    Patton, D
    Gordon, LI
    Riley, MB
    Kuzel, T
    Tallman, MS
    Rosen, ST
    LEUKEMIA & LYMPHOMA, 2004, 45 (11) : 2269 - 2273
  • [43] Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study
    Deng, Rong
    Gibiansky, Leonid
    Lu, Tong
    Li, Xiaobin
    Lu, Dan
    Li, Chunze
    Girish, Sandhya
    Wang, Jue
    Boyer, Michelle
    Shankar, Noopur
    Humphrey, Kathryn
    Freise, Kevin J.
    Salem, Ahmed Hamed
    Seymour, John F.
    Kater, Arnon P.
    Miles, Dale
    LEUKEMIA & LYMPHOMA, 2020, 61 (01) : 56 - 65
  • [44] Genasense (Bcl-2 antisense) monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: Phase 1 and 2 results.
    Rai, KR
    O'Brien, S
    Cunningham, C
    Turkina, AG
    Ochoa, L
    Frankel, SR
    Golenkov, AK
    BLOOD, 2002, 100 (11) : 384A - 384A
  • [45] ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study.
    Ma, Shuo
    Seymour, John Francis
    Lanasa, Mark C.
    Kipps, Thomas J.
    Barrientos, Jacqueline Claudia
    Davids, Matthew Steven
    Mason-Bright, Tanita
    Rudersdorf, Nikita
    Yang, Jianning
    Munasinghe, Wijith
    Zhu, Ming
    Cerri, Elisa
    Enschede, Sari H.
    Humerickhouse, Rod
    Roberts, Andrew Warwick
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [46] Rituximab and Campath-1H combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
    Nabhan, C
    Patton, D
    Gordon, LI
    Riley, MB
    Kuzel, T
    Tallman, MS
    Rosen, ST
    BLOOD, 2003, 102 (11) : 361B - 361B
  • [47] Phase II trial of the combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)
    Falchi, Lorenzo
    Keating, Michael J.
    Badoux, Xavier C.
    Wierda, William G.
    O'Brien, Susan Mary
    Smith, Susan C.
    Wen, Sijin
    Kantarjian, Hagop
    Ferrajoli, Alessandra
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] Acalabrutinib with Obinutuzumab in Relapsed/Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia: The Phase 1b/2 ACE-CL-003 Study
    Woyach, Jennifer A.
    Awan, Farrukh T.
    Jianfar, Mojgan
    Rogers, Kerry A.
    Jones, Jeffrey
    Covey, Todd
    Hamdy, Ahmed
    Izumi, Raquel
    Patel, Priti
    Wang, Min Hui
    Byrd, John C.
    BLOOD, 2017, 130
  • [49] A Phase I Clinical Trial of CLL-1 CAR-T Cells for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia in Adults
    Zhang, Xiaomei
    Lv, Hairong
    Xiao, Xia
    Bai, Xue
    Liu, Pengjiang
    Pu, Yedi
    Meng, Juanxia
    Zhu, Haibo
    Wang, Zhao
    Zhang, Huan
    Zhang, Yu
    Lv, Cuicui
    Ma, Li
    Yuan, Ting
    Zhang, Meng
    Sun, Rui
    Zhao, Yifan
    Cao, Xinping
    Guo, Ruiting
    Zhang, Yi
    Guo, Shujing
    Liu, Jile
    Zhao, Mingfeng
    BLOOD, 2023, 142
  • [50] Initial Results of the Phase 2 Treatment Naive Cohort in a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia
    Rogers, Kerry A.
    Huang, Ying
    Stark, Amy
    Awan, Farrukh T.
    Maddocks, Kami J.
    Woyach, Jennifer A.
    Whitlow, Thomas
    Byrd, John C.
    Jones, Jeffrey A.
    BLOOD, 2017, 130
12345